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ABSTRACT 
Most recent epidemiological studies point out that depression is one of the most common diseases 
among general population and it is recognized as a major public health problem. The primary goal 
of depression treatment consists of the complete resolution of symptoms and thus in the total 
healing. Clinical experience and literature data indicate that, with current treatments, only a small 
percentage of patients achieves a full symptom remission. The results of the STAR*D, which 
focused on the effectiveness of treatments, showed that one-third of depressed patients will never 
reach complete recovery even after multiple drug trials
5.
. From these data emerges that treatment 
resistance is quite common among patients with Major Depressive Disorders and accounts for an 
important part of human suffering and social burden caused by depression
6-7
. 
In the present study we examined a sample of depressed inpatients during a one-year naturalistic 
follow-up. The aims of the study were: 1) to investigate the demographic and clinical characteristics 
associated with Treatment Resistant Depression (TRD); 2) to evaluate the prospective course and 
outcome of illness over a one-year naturalistic follow-up; 3) to compare the clinical and 
demographic variables of treatment-resistant patients with a group of patients matched by sex and 
diagnosis, who adequately responded to the drug treatment 
A consecutive series of subjects, aged 18-70 years, hospitalized in our centre, with a Major Unipolar 
or Bipolar Depression diagnosis recruited from January 2008 to January 2009 were included in the 
analysis (TRd: Treatment resistant depressives) . Patients with a primary diagnosis of Unipolar 
MDD or BPD; stage I of Thase & Rush criteria for resistance to treatment  and  a baseline 
Montgomery-Asberg Depression Scale (MADRS)
149
 score > 21 were included in the study and 
were enrolled in the 12 months naturalistic follow up . Afterwards, we screened a sample of 47 
outpatients matched by sex with the same inclusion and exclusion criteria, except that of treatment 
resistance, in fact they began antidepressant treatment  not later than two months before with 
positive response.(Rd: Responder depressives) 
In our study TRD population is mainly composed by middle aged female, married, with high level 
of education. TRD patients report a  personal  history of treatment resistance and personal and 
familiar history of suicide attempts. A bipolar diathesis may represent an important clinical 
characteristics of TRD patients, too. Treatment resistance appears mainly related to melancholic 
episodes, duration of the current episode, number of previous depressive episodes and 
hospitalizations, and suicide risk. Somatic comorbidity (specifically cardiovascular diseases), Axis I 
disorder comorbidity, particularly anxiety disorders (Panic Disorder) may be highly frequent in 
TRD population. During the follow up year the majority of the TRD patients examined (63.8%) 
have a remission and about 20% of the sample have a recovery. 
Although TRD is a common clinical occurrence, a greater consensus is required regarding the 
definition and the operational criteria for staging response and resistance to antidepressant 
treatments. Predictive factors must be identified to recognize patients who are more likely to 
respond to antidepressant trials. Pharmacogenomic studies are also needed to assist in identifying 
biological predictive factors.    
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1. INTRODUCTION 
 
Most recent epidemiological studies point out that depression is one of the most common 
diseases among general population and it is recognized as a major public health problem: the 
World Health Organization Global Burden of Disease Survey anticipates that by the year 2020 
major depression will be second only to ischemic heart disease in the amount of disability 
experienced by sufferers
1
. It has been estimated that over 340 million people worldwide are 
suffering from depression, while the lifetime prevalence of major depressive episode is a little 
less than 17%
2
. Burden of depression consists not only of the high health care costs, but also of 
the high human and social costs. This is mostly due to the high tendency to recurrences: it is 
reported that over two thirds of patients may present recurrences; after the first episode, the 
likelihood of a relapse is 50%, while after a second episode the probability of a third one is more 
than 90%
3
. 
The primary goal of depression treatment consists of the complete resolution of symptoms and 
thus in the total healing: more than half a century of research has made available a great number 
of antidepressant agents from many different pharmacological classes, yet the therapy of 
depressive syndrome remains far from needs of patients and clinicians. Clinical experience and 
literature data indicate that, with current treatments, only a small percentage of patients achieves 
a full symptom remission. The results of the STAR*D, which focused on the effectiveness of 
treatments, showed that only half of patients responds to an initial antidepressant trial and an 
even smaller percentage, around 30%, achieves clinical remission
4
. Morover, one-third of 
depressed patients will never reach complete recovery even after multiple drug trials
5.
.  
From these data emerges that treatment resistance is quite common among patients with Major 
Depressive Disorders and accounts for an important proportion of human suffering and social 
burden caused by depression
6-7
. The development of knowledge about clinical characteristics, 
biological correlates and therapeutic strategies of Treatment Resistant Depression (TRD) is then 
crucial, and recently researchers' interest on this issue had recently increased . 
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Patients with TRD are at a greater risk of relapse, suicide and substances abuse, frequently show 
comorbid psychiatric disorders and/or physical abuse and suffer from a significant and prolonged 
impairment on the social, occupational and interpersonal functioning 
6,7,8,9,10 
.
   
 
2. DEFINITION 
The concept of TRD has been introduced in the literature in 1974
11,12
. Since then, a large amount of 
study have been published on this topic, maybe stimulated by the increasing availability of new 
antidepressant molecules. The interpretation of the research data is limited by the extreme 
heterogeneity of the descriptions and definitions of treatment-resistant depression: these latter range 
from the non-response to a single antidepressant treatment, adequate in terms of duration and 
dosage, to the partial or no response to multiple antidepressant trials of different pharmacological 
classes, and to electroconvulsive therapy (ECT)
3,14,10,15
. There are not unique criteria for assessment 
of response to treatment, defined in clinical trials as an improvement of at least 50% of the initial 
depressive symptoms after four weeks of treatment. The differences are related both to the type of 
rating scale adopted for the measurement of depressive symptoms (Hamilton Depression Rating 
Scale HAMD vs. Montgomery- Asberg Depression Rating Scale- MADRS) and to the cut-off score 
required for the definition of response to treatment. There are also disagreements about 1) the 
minimum duration 2) dosage of the prescribed antidepressant 3) the type and number of  trials 
before the diagnosis of TRD
13,14
. In recent years, a broad consensus on the definition of TRD has 
been reached “a major depressive episode that didn’t show significant clinical improvement after at 
least two consecutive trials with antidepressants of different pharmacological class, adequate  in 
terms of duration and dosage of the drug”16,17,18,19,14. Data from the STAR*D on the gradual 
reduction of the probability of response to antidepressant treatment after the second trial, would 
seem to support the validity of this concept
4,14,15
; and recently the European Medicines Agency 
(EMEA) has essentially confirmed the assessment criteria of resistance to antidepressant treatment, 
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defining the TRD "a depressive episode that does not benefit from at least two adequate trials of 
antidepressants with different mechanism of action"
20 
Nevertheless at least two methodological objections against this definition raised: the first is related 
to the implicit assumption that the lack of response to two drugs of different molecular class 
represents a condition of greater severity than the non-response to two trials with antidepressants of 
the same class. The second concerns instead the postulate that derives from major effectiveness of 
the switch between different classes of antidepressants compared to intra-class switch (this postulate 
could affect treatment decisions). Both of these assumptions, are not clearly supported by evidence 
from clinical trials
14,15,8
. Recently, some authors have also pointed out the contradiction between the 
dichotomous approach of the criteria defining the response/resistance to treatment and clinical 
observations on the dimensional nature of the TRD. An ideal system for staging TRD should be able 
to distinguish between depressive symptoms according to their level of resistance to drug treatment, 
predict the likelihood of remission in subsequent trial and address the choice of further treatments: 
this characteristics are more easily satisfied by a dimensional model rather than by a dichotomous 
model. In particular, it has been proposed to conceptualize the TRD on the model of the "spectrum", 
ie on the line of a continuum that extends from the failure to respond to a single antidepressant, up 
to the lack of response to different classes of antidepressants and finally to strategies of 
"strengthening", including the ECT
10.17
. It has been also shown that the definitions proposed so far 
are based only on the results of previous drug treatments, excluding psychological therapies 
eventually made by the patient, such as cognitive-behavioural psychotherapy (CBT) or 
interpersonal psychotherapy (IPT)
21
. In any case, none of the staging systems currently available 
has been systematically evaluated with prospective studies in terms of reliability and predictive 
value . 
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3. STAGING 
The different staging methods:  
a)Antidepressant Treatment History Form
22
. 
b)Thase and Rush Staging Method
 25
. 
c)The European Staging Method
36
. 
d)Massachusetts General Hospital Staging Method
 8
. 
e)Maudsley Staging Model
 6
. 
are summarized in Table n°1 . 
4. DIFFERENTIAL DIAGNOSIS 
Some conditions must be considered in the differential diagnosis of TRD (see Table 2). 
Pseudo-resistance refers to a  condition where the non response to therapy is attributable to factors 
external to treatment’s action. The term has been introduced by Nierenberg and Amsterdam in 
1990
41
, to indicate cases where the non-response to therapy was due to the inadequacy of the 
treatment , in terms of duration or dosage
41
. Some data from literature suggest that less than half of 
depressed patients receives adequate antidepressant treatment with standard doses for a period of 
time long enough to induce a clinically significant effect
42
. Low doses of antidepressant drugs are  
historically recognized as a major cause of lack of response to treatment
15,18
 Concerning tricyclic 
antidepressant (TCA) depression treatment’s main  guidelines consider appropriate a trial with no 
less than 250-300 mg/day of imipramine (or equivalent) and , in the case of  monoamine oxidase 
inhibitors MAOIs, a trial of 90 mg/day of phenelzine (or equivalent )
27,36
. For selective serotonin 
reuptake inhibitors (SSRIs) and new-generation antidepressants (NARI, NaSSA) no precise criteria 
to define the appropriate dose of the drug is still available, since the relationship between dose- 
plasma level and response to therapy is still not clear and needs further clinical and pharmacological 
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studies . 
Moreover a correct evaluation on treatment’s adequacy cannot therefore prescind from the 
assessment of the drug's effects on the metabolism by the potential variability factors such as age, 
sex , body weight, general physical condition, genetic characteristics and drug interactions. For 
example, during clinical and therapeutic management of non-responder depressed patients the 
detection the  antidepressant plasma levels can be useful to exclude a low blood level. It can be due 
to the concomitant prescription of drugs that induce metabolism or to genotypic characteristics of 
the patient wich may influence the antidepressant plasma levels.  In recent years, the role of the 
genes involved in the metabolism of drugs and xenobiotics such as the transmembrane transporter 
ABCB1, better known as P-glycoprotein , isoenzymes CYP2D6 and CYP2C19 cytochrome P450
43 
has been increasingly evident. A variation of plasma levels of nortriptyline in relation of the degree 
of activity of CYP2D6 has been proved; in a recent Swedish study which examined of subjects with 
two different genotypes of CYP2D6 (fast and slow metabolizers), authors found that about 90% of 
patients refractory to drug (that was metabolized by cytochrome 2D6) were in the rapid metabolizer 
subgroup
44
. However, the role of the cytochrome P450 on the outcome of treatment is still 
controversial, in facts, the results of recent surveys did not confirm an association between genotype 
for the isoenzymes CYP2D6, 2C19 and response to antidepressant trials
45,46
. Evaluation of the 
adequacy of an antidepressant treatment is also based on duration of therapy. Most of the studies 
have considered as optimal a period of  4-6 weeks, however, these studies have been sponsored by 
the pharmaceutical industry, in order to determine statistically significant differences between the 
drug and the placebo
14,47,15
. In the literature on TRD is pointed out the necessity, particularly in 
special patients populations, to prolong the treatment beyond the standard period of four weeks, 
before assuming the ineffectiveness. The data from several studies that have found clinical 
remission of depression by prolonging the duration of the trial over 10 weeks in partial-responder 
patients
47,48,19
 supports this position. In particular, in elderly depressed patients, it is frequent the 
need of prolonging the treatment to at least 12 weeks prior to appreciating a significant 
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improvement 
10,49
 .  
In psychiatry, as in every other medical discipline, treatment compliance is a crucial aspect: 
according to some data up to 20% of  refractory to antidepressant treatment cases is attributable to 
the lack of patient adherence to therapeutic requirements. In these cases it may
13,14,15 
be necessary to 
strengthen the therapeutic alliance between psychiatrist and patient even with a psychoeducational 
intervention, marked by the information on the characteristics of the disorder, the nature of the 
symptoms , the course, the discussion on the effects of drugs , the expected results and the duration 
of treatment. 
Another external factor of potential resistance to treatment is a wrong diagnostic classification. 
Even in this case it would be more appropriate to speak of "pseudo-resistance",  among the 
common causes are: the non-recognition of a somatic disorder in comorbidity with depression as 
a endocrine disease (hypothyroidism, Cushing's disease), a neurological disease (multiple 
sclerosis , parkinsonism, etc) or substance abuse (including benzodiazepines)
9,15
 . 
A diagnosis re-evaluation also includes a careful assessment of the symptomatic characteristics 
of depression, actually some depressive subtypes respond less favorably to antidepressant 
treatment and require specific therapeutic intervention
9,15
. For example, melancholic depression 
wich distinguished for psychomotor retardation, late insomnia, hyporexia and worse mood in the 
morning, would have a preferential response to TCA and ECT, while the depressive syndromes 
with atypical features such as mood reactivity, interpersonal sensitivity and inverse pattern of 
neurovegetative disorders (hypersomnia, hyperphagia), have more likely to respond to treatment 
with MAOIs or SSRIs compared with TCA
50
. Finally, in depression with psychotic symptoms 
monotherapy with antidepressants is generally ineffective and not reccomanded, the combined 
treatment with antipsychotics or ECT is instead indicated
51
. 
In 2001, Kornstein and Schneider identified major risk factors of treatment antidepressant 
resistance as: comorbid psychiatric disorder, comorbid medical condition, advanced ageing, 
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symptoms severity and chronicity of course
9
. 
The survey on risk factors for non-response /resistance to treatment is an important chapter of the 
literature on TRD. The European Group for the Study of Resistant Depression (GRSD) showed 
11 variables correlated with resistance to treatment in a sample of 702 patients with a diagnosis 
of Major Depressive Episode: comorbidity with anxiety disorders, suicidal ideation, severity of 
the pre-treatment symptoms and an history of failure to respond to the first antidepressant 
treatment
27,28 
Psychiatric comorbidity is therefore reported in the literature as one of the major clinical 
predictors of resistance to antidepressant treatment . In particular, the role of comorbidity with 
anxiety disorders has been emphasized: in GRSD study, 39.3% of patients with treatment-
resistant depression also had a Axis I diagnosis of anxiety disorder.  
The correlation between comorbid anxiety and poor response to treatment
52,53
 is strong, for 
example the results of recent study, indicated the concomitant use of anxiolytics as a predictor of 
treatment resistance in elderly patients with depression
54
. The negative impact of comorbidity 
anxiety disorders on response to antidepressant treatment seems to be attributable particularly  to 
some clinical forms. In GRSD study, the more frequently reported comorbid diagnosis among 
resistant depressed patients was Panic Disorder, while in the other two studies, the presence of 
lifetime  panic-agoraphobic spectrum symptoms in depressed patients was associated with a poor 
response to interpersonal psychotherapy 
56
 and  pharmacotherapy
55
.  
Finally, it is necessary to mention the role that other psychiatric comorbidities can have on the 
antidepressant treatment's outcome. In particular we have gathered extensive evidence in the 
literature on the correlation between substance abuse and TRD
57
: even a moderate consumption 
of alcohol can contribute to refractoriness to antidepressive therapy
58
 . 
The role of comorbidity with personality disorders seems rather controversial: data on the 
correlation with a poor response to antidepressant treatment reported by some studies
59,60,61
 have 
not been confirmed by subsequent paper 
62,63,64
. 
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Medical comorbidity has been identified as an important risk factor for resistance to treatment; 
according to the literature, the coexistence of physical pathology is detectable in about one  half 
of patients admitted for depression and besides it seems to modulate the clinical presentation and 
to affect also the outcome of the treatment
9,66
. One of the most studies medical comorbidity in 
depressed patients is thyroid disease: subclinical hypothyroidism forms has been observed in 
more than half of depressed patients with refractoriness to treatment
68
. 
Other laboratory evidences found in treatment-resistant depressive patients are hypercalcemia, 
vitamin B12 and folate deficiencies. Finally, in the recent years, there has been increased 
recognition that silent cerebrovascular disease, especially involving subcortical-frontal brain 
circuits, may impair response to antidepressants
242
. It has been reported that the pre-treatment 
severity of depression and other common clinical indicators of severity, such as the long duration of 
the episode, the high recurrence, the number of hospitalizations, early age of onset and a positive 
history of failure of previous antidepressant therapies, are risk factors for resistance to 
antidepressant therapy
9,28
. A poor response to treatment may also be conditioned by individual 
symptom aspects, such as the presence of melancholic features or psychotic symptoms
8,9,28
. 
The presence of suicidal ideation may affect the outcome of antidepressant treatment: two studies 
that compared TRD patients with non-resistant depressed patients, found that the presence of 
suicidal intentions was more frequent in patients with refractoriness to treatment
69,70
. 
Concerning the role of demographic variables the available evidences are not conclusive: some 
previous studies had associated female gender to poor response to treatment, but the most updated 
data, have instead reduced the weight of gender, pointing out however in subjects of female sex 
decreased likelihood of response to particular classes of antidepressants such as TCA
9
.
71,72
 . 
5. RESISTANCE TO TREATMENT AND BIPOLAR DIATHESIS 
Since 1987, Akiskal and Mallya had included non-response to antidepressants among the criteria for 
soft bipolar spectrum
73
. Subsequent studies seem to confirm this report: the non-response to 
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antidepressants can be considered an indicator of bipolarity and, on the other hand, the presence of 
bipolar clinical aspects or of bipolar prospective course, even attenuated, often underlie the 
refractoriness to treatment antidepressants.  
Sharma et al. (2005)
74
 conducted a follow-up study of a sample of TRD unipolar patients. For an 
accurate diagnosis of the subsequent revaluation , carried out with standardized instruments such as 
the Structured Clinical Interview for DSM -IV (SCID)
75
 and with the criteria for Bipolar Disorder 
Spectrum
76
, 59% of these patients received a diagnosis of Disorder bipolar I or II while more than 
half of the sample appeared to meet the criteria for the bipolar spectrum
76
. Overall, about 80% of 
the sample showed significant evidence of bipolar diathesis
74
. Subsequent studies of a prospective 
nature, have confirmed the relationship between resistance to treatment and evolution of bipolar 
affective disorder: in a survey of follow-up of depressed patients initially diagnosed with unipolar 
depression, the probability of conversion to bipolar disorder was statistically higher among patients 
with resistance to antidepressant therapy compared to responders patients
77
 These results are in line 
with data from even more recent study
78
 that have observed, in patients with unipolar depression, 
the association between a drug history of poor response to antidepressant treatment and the 
probability of evolution in bipolar disorder. Finally the results of the European multicenter study 
Treatment Resistant Depression in Project
79
. indicate bipolarity, as assessed with the Mood Disorder 
Questionnaire (MDQ) and the Hypomania Checklist (HCL- 32), as a risk factor for non- response to 
antidepressant treatment in the depressed patient. Based on the evidence some authors have 
advanced the hypothesis that, at least in some cases, resistance to treatment could recognize an 
iatrogenic origin, or could be a consequence of a not correct prescription of antidepressant drugs in 
a patient with unrecognized bipolar diathesis
65, 80
. In support of this hypothesis, it should 
remembered some of the effects of antidepressant therapy, usually described in bipolar depressed 
patients but also commonly observed in resistant unipolar depression. One of these cases, for 
example, is the phenomenon of "wear-off", which consists in the gradual loss of the therapeutic 
efficacy of the antidepressant, after the initial response in the acute phase of the treatment, with the 
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consequent return of depressive symptoms in the later stages of maintenance and/or prophylaxis. 
Other typical result of the use of antidepressants in bipolar depression is represented by the 
progressive loss of efficacy in antidepressant trials thereafter ("refractoriness")
81
 is also considered 
a sign of the onset bipolar diathesis, in connection with the intake of antidepressants, symptoms of 
thymic sphere (irritability), psychomotor (restlessness) and cognitive (ideas acceleration) 
dimensions that tend to set up a framework of attenuated mixed state or mixed depressive 
syndrome
80, 81
 . 
In fact, with regard to the relationship between bipolar diathesis and response to antidepressant 
there is still an open debate far from a resolution. Ghaemi (2008)
65
 tried to argue the thesis of the 
fundamental role played by soft bipolarity in the resistance to antidepressants concluding that, as 
indicated by the results of the studies of effectiveness STAR*D and STEP-BD, the inability to 
recognize bipolar symptoms within depression is the major cause of the limited efficacy of 
antidepressants in the treatment of depression. On opposite side are the considerations of Perlis and 
coll. (2011)
82
: according to these authors, in fact, the simple observation that the non-response to 
antidepressants is associated more frequently with some symptoms such as irritability and 
psychotic-like events, though indicators of bipolarity, not necessarily leads to the conclusion that 
the bipolar spectrum is correlated with resistance to treatment; in fact, the non-response, could be 
correlated to the individual symptomatic aspects. 
It is worth remembering that different contributions may connect the prescription of antidepressants 
(also in combination with mood stabilizers) with an increased incidence of suicidal behaviour in 
depressed patients with bipolar diathesis. It has been suggested that in the first weeks of treatment 
antidepressants are more effective on the motor component with respect to the ideational 
component and mood. Therefore, in patients who have risk factors for suicide in the short term 
(anxiety, insomnia, dysphoria, agitation) antidepressant therapy could result in a boost to the action 
and the worsening of anticonservative actions
145
. According McElroy and colleagues (2006) in 
these cases there would be a "partial" manic switch, where only the psychomotor component, but 
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not the cognitive (which remains "fixed" on the experiences of incurability, hopelessness and 
pessimism), would suffer a sudden and abrupt colour change in the sense of 'activation
146
 in these 
forms of depression, which correspond to a attenuated mixed state.  Moreover, antidepressants 
treatments leads to a further destabilization of mood toward rapid cycling, chronicity, and the 
increased risk of suicide in time
147 
 
6. PSYCHOPHARMACOLOGICAL TREATMENT STRATEGIES 
Once you have completed the diagnostic procedure to confirm the presence of a treatment-resistant 
depression, the clinician has various pharmacological strategies: 
1. Increasing the dose and/or duration of the current treatment (optimization); 
2. Replacing the first antidepressant drug with a second belonging to the same pharmacological 
class or a different class (switching intra-class or inter-class); 
3. The addition of a second antidepressant to the current treatment (combination); 
4. Adding to antidepressant treatment, a drug dose which doesn’t have a direct antidepressant action 
(augmentation) . 
 
6.1 Optimization 
The so-called optimization of the regimen, which includes an increase in the dose or the extension 
in time of the use of the antidepressant (also over 6-8 weeks), can be particularly useful in patients 
who have shown a partial response to treatment, without the development of significant side effects 
, or in special populations such as in old patients or patients with medical comorbidities. Increasing 
the dose (even at higher levels than the standard ) may allow the achievement of therapeutic plasma 
levels in patients rapid metabolizers of CYP2D6 (approximately 80-94 % of the Caucasian 
population) or may allow a different action profile of neuro- receptor (for example, a noradrenergic 
stimulation by SNRI venlafaxine, that at lower doses has a predominantly serotonergic action) 
83 
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The drug dosage should be increased, up to the maximum recommended dose, until any one of the 
following conditions occurred: a) remission of symptoms, b) occurrence of dose-limiting adverse 
effect
84
. 
The rationale for increasing antidepressants treatment’s duration comes from the observation that a 
substantial number of depressed patients would be "late responders": 53% of patients treated with 
TCA, in fact, respond beyond the sixth week of antidepressant treatment
87
. In literature , however, 
data supporting the extension of therapy beyond 6-8 weeks are conflicting 
 
6.2 Switching 
In case of no response or intolerance to the drug, a viable option is represented by the replacement 
of the antidepressant with another drug belonging to the same class (intra-class switch) or a 
different one (switch inter-class). With respect to combination strategies/upgrading the switch 
allows avoiding the administration of different kinds of drugs, the main reason for poor compliance, 
and from an economical point of view it is also advantageous. The main disadvantages consist in 
the loss of the positive effects of the first antidepressant used, the delay of onset of therapeutic 
effect and the necessity of a period of cross- titration or wash-out. 
Until a few years ago, the guidelines usually recommended switching to a different class of 
antidepressant in order to obtain a different neurochemical action based of different 
neurotransmitters and to research differential responses in various subtypes of depression: 
according to some data found in literature a profile of melancholic symptoms respond to TCA, 
while SSRI antidepressants or MAOIs would be more indicated in the atypical forms of depression 
90
. Poirier and Boyer (1999)
91
,  in their studies, show a greater effectiveness switching from an 
SSRI to venlafaxine (SNRI: Serotonin Noradrenaline Reuptake Inhibitor) compared to intra- class 
switch . In addition, other studies show that the therapeutic response rates was much higher when 
switching from an SSRI to a TCA ( 16.5 to 48.5 %), although with a higher percentage of drop-outs 
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related to side effects
30,84
. Other studies including STAR*D, however, revealed a substantial overlap 
in response rates between inter- and intra- class switches
37, 92
 . 
Finally some data underline the benefits, both in terms of increased likelihood of remission and  
better tolerability, from the replacement of an SSRI with another. In fact according to a meta - 
analysis carried out by Ruhe and colleagues (2006)
32
, 50% of patients do not respond to a first SSRI 
and switch to second SSRI: 70 % of patients who discontinue a first SSRI for side effects, tolerate 
and respond to the second. The cross- tolerance between the compounds also would allow a faster 
replacement
93
.Some studies seem to show that patients not responsive to SSRI antidepressant could 
be responsive to antidepressant with a different mechanism of action such as bupropion, or 
duloxetine
95
. Also Baldomero and colleagues (2005)
96
 reported a higher rate of response after 
switch to venlafaxine rather than to another SSRI. A more recent meta-analysis of controlled 
clinical trials, then, has shown that the switch to another antidepressant does not bring benefits with 
respect to continuation of existing treatment 
94
 . 
6.3 Combination and augmentation 
Multipharmacological treatment strategies, such as combining and upgrading, are generally chosen 
in case of partial antidepressant response or non- response in the absence of significant side effects. 
They offer some advantages compared to monotherapy: first, they can help clinicians to avoid the 
loss of the therapeutic benefits of the treatment of first choice, also reducing the risk of withdrawal 
symptoms then,  these strategies have a lower latency effect. A further advantage is therefore the 
ability to expand the range of action of the treatment, acting on different neurotransmitter systems , 
associated with different psychopathological dimensions
83
 By contrast, however,  polypharmacy 
may reduce adherence to prescriptions, it may expose patients to the risk of possible drug 
interactions and finally, it may lead to an increase of treatment’s economic costs. 
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6.4 Combination 
The combination of antidepressants is generally a second choice in case of non-response to two 
following drug trials but it could be the first choice in patients with severe forms of depression. 
Some authors point out that the appeal in the first instance to a combined treatment can meet the 
needs of an "aggressive" treatment of depression, as it promotes a rapid and complete resolution of 
symptoms, minimizing the risk of treatment resistance which is connected to an early relapses and 
persistence of residual symptoms
97
  
6.5  Augmentation 
In case of non-response or partial response, a viable alternative option is also represented by the 
enhancement of treatment with drugs that don’t have a direct antidepressant action; in literature 
there are numerous studies on the augmentation of antidepressants with the addition of lithium, 
atypical antipsychotics, thyroxin, dopamine agonists, psychostimulants
38,99
. A critical opinion on the 
effectiveness of upgrading strategies is hampered by some important limitations of existing studies 
in literature: a case series of patients treated mostly numerically small; the frequent arbitrariness in 
the choice of the potentiating agent, that comes from experience and personal preference of the 
researcher; the availability of a few controlled trials in which the antidepressant "enhanced" was, in 
most cases, a tricyclic drug
98
 . 
The drugs most frequently used in the strategies of augmentation are:    
Lithium salts: through an enhancement of serotonergic transmission
94 
Triiodothyronine (T3) by increasing noradrenergic transmission
100 
 Dopamine agonists    
Amantadine 
101,102,103
 Pramipexole: ropirinole 
104,105 
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 Buspirone: partial agonist 5HT
138 
-Atypical antipsychotics via agonist action on serotonergic 5HT2 
Aripiprazole, Ziprasidone (even partial agonist on 5HT1A receptors) 
Olanzapine Risperidone: Quetiapine (along with Ziprasidone also inhibitory effects on reuptake of 
norepinephrine)99,106 . 
Paliperidone, Asenapine: there are no data on their effectiveness as a strategy for strengthening the 
non-response to antidepressants
107 
Pindolol: it acts as a receptor agonist 5HT1
108 
-Psychostimulants: For their property to stimulate the dopaminergic serotonergic and 
noradrenergic system. 
Classical psychostimulants (amphetamine-like) methylphenidate has not been shown to affect the 
rates of response and remission in patients with resistant depression, although in these studies there 
has been an improvement in symptoms such as fatigue and apathy 
109,110,111
   
 Modafinil: it acts with a different mechanism of action compared to classical psychostimulants, 
acting primarily on the dopaminergic and noradrenergic transmission and secondarily on the levels 
of serotonin, histamine and glutamate (causing an increase). It would have also an action on the 
orexine system
112
. Regarding Modafinil have been reported interesting data in depressed patients 
with hypersomnia and asthenia. In these subjects, in fact, the literature data suggest a role of 
Modafinil in increasing response rates to antidepressant therapy113,114,115. 
Lamotrigine: inhibitory activity of the glutamate presynaptic release116,117 
Sex hormones: testosterone andestrogen (mixedresults) 
118,119,120,121,122,123 
-Dietary supplements: Omega 3226, S-adenosylmethionine (SAM)
141,142
, Tryptophan
143
,  Folic 
Acid
144
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New studies on augmentation trials concerning: drugs acting on the cholinergic system reported that 
the cholinergic antagonist mecamylamine has shown good properties in empowering therapy with 
SSRIs (citalopram)
124 
Drugs acting on NMDA receptors: the study of memantine (NMDA antagonist) gave 
disappointing results
125
, while ketamine (NMDA antagonist, used as an anaesthetic) showed 
antidepressant properties interesting to be explored in future studies
126
. However, the intravenous 
administration limits the indication for the most severe patients; the therapeutic efficacy of 
ketamine also runs out at the end of the dosing period, with an average period to relapse of 
approximately 18 days after the last infusion. Therefore, researchers are trying to develop in order 
strategies to maintain the therapeutic effect
127
. Also
 
 the risk of significant side effects (especially 
hallucinations and derealisation)
128 
not be neglected . 
-The Riluzole, an inhibitor of the release of glutamate used in the treatment of amyotrophic lateral 
sclerosis, showed a good enhancement effect on antidepressant therapy in a small open-label study 
129
. 
7. PHYSICAL STRATEGIES FOR TREATMENT 
In treatment-resistant depression, in addition to drug therapy, various therapies for brain stimulation 
involving the application of physical intervention or by means of electric current or magnetic field, 
and addressed to specific areas of the brain or generalized , may be taken into consideration: 
Electroconvulsive therapy (ECT)
130 ,131 
Vagus nerve stimulation (VNS)
132,133 
Repetitive transcranial magnetic stimulation (rTMS)
134,135
. 
 
Magnetic convulsant therapy (MST)
136 ,137
. 
 
Transcranial direct current stimulation (tDCS)
139 
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Deep brain stimulation (DBS)
138  
Finally still be considered experimental Stimulation Bilateral Epidural Prefrontal Cortical (EPCs) 
described by a research group of South Carolina University
148
 . 
In conclusion, despite the importance of treatment-resistant depression plays to date in terms of 
morbidity and mortality, treatment protocols currently available are still inadequate for the needs of 
the clinician and patient expectations. Therefore, we feel the need for further studies, which use 
criteria definition and validation universally accepted, drawn on case studies large enough to 
develop new therapeutic options based on clinical evidence . 
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8. AIM OF THE STUDY  
In the present study we examined a sample of depressed inpatients during a one-year naturalistic 
follow-up. The aims of the study were:  
a) to investigate the demographic and clinical characteristics associated with TRD 
b) to evaluate the prospective course and outcome of illness over a one-year naturalistic follow-
up   
c) to compare the clinical and demographic variables of treatment-resistant patients with a 
group of patients matched by sex and diagnosis, who adequately responded to the drug 
treatment 
 
9. MATERIALS AND METHODS 
 
9.1 Subjects 
Depression Treatment Resistance Centre in Psychiatric Clinic of Pisa in Italy is a tertiary care centre 
which receive depressed patients non responder to pharmacologic treatment from the whole national 
territory. A consecutive series of subjects, aged 18-70 years, hospitalized in our centre, with a Major 
Unipolar or Bipolar Depression diagnosis recruited from January 2008 to January 2009 were 
included in the analysis (TRd: Treatment resistant depressives) All patients received a diagnosis of 
Major Unipolar (MDD) or Bipolar Depression (BPD) according to DSM IV-TR criteria. Previous 
antidepressant treatment resistance according to Antidepressant Treatment History Form (ATHF, 
Sackeim et al.,1990)
22
 criteria were assessed in all patients. Afterwards, a stadiation of resistance 
according to Thase & Rush
25
 were established for each patient.  
Inclusion criteria were 1) patients with a primary diagnosis of Unipolar MDD or BPD, 2) stage I of 
Thase & Rush criteria for resistance to treatment (“failure to achieve remission after at least one 
antidepressant trial of one major class of antidepressant at adequate dose, the dose used was equal 
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to or higher than the lowest dose defined as effective in the product datasheet, and duration at least 
4 weeks”), and 3) a baseline Montgomery-Asberg Depression Scale (MADRS)149 score > 21 was 
needed to be included in the study.  
Exclusion criteria were: 1) patients with a mood disorder secondary to any primary “nonaffective” 
psychiatrc condition, 2) patients unable to understand or provide written informed consent, 3) age< 
18 or >70 years and 4) acute somatic illness (kidney and liver failure, presence of a serious heart 
condition, epilepsy or conditions predisposing to epilepsy, other neurological diseases,  pregnancy, 
substance abuse over the previous six months or drug dependence)  
The study protocol was approved by the ethical committees of University of Pisa.  
After a complete description of the study, 47 patients (Rd: Responder depressives) who met 
inclusion criteria signed a written informed consent and were enrolled in the 12 months naturalistic 
follow up .  
Afterwards, we screened a sample of 47 outpatients matched by sex with the same inclusion and 
exclusion criteria, except that of treatment resistance, in fact they began antidepressant treatment  
not later than two months before with positive response. 
 
9.2 Assessment 
Axis I diagnosis was made according DSM-IV-TR criteria
177
 by means of Structured Clinical 
Interviews (SCID-IV)
75
. Montgomery-Asberg Depression Scale (MADRS)
149
 and CGI scale 
(Clinical Global Impression Severity)
 150
 were used to estabilish symptoms and severity of episode. 
Number of weeks of remission , relapses, hospitalizations, suicide attempts, and pharmacological 
therapies was been evaluated using the LIFE scale (Longitudinal Follow up Evaluation).  
Patients were evaluated using LIFE, MADRS and CGI at enrollment and after 4,8,16,32,48 weeks, 
in order to examine the prospective course of the disorder.  
All psychiatric evaluations have been conducted by two trained psychiatrists who were blinded to 
diagnosis and treatment.  
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For the sample of Responder the diagnosis of Major Depression was made retrospectively on the 
basis of clinical interview conducted at the patient and his family members and on the basis of 
recordings in outpatient folder. 
 
9.3 Outcome definition 
The main outcomes of interest were response, remission, recovery, relapse and recurrence. 
Response: reduction of the initial score of the MADRS scale ≥ 50% 156 
Remission: temporary abatement (at least 8 weeks) of symptom: the individual no longer meets 
syndromal criteria for the disorder (MADRS score≤12, HAM-D score<7)157  
Recovery: It implies a more sustained remission (at least 6 months) and raises the possibility that 
treatment can be discontinued or prolonged with the aim of prevention
157,158
. 
 Relapse: the return of a disease after its apparent cessation (during the period of remission) 
Recurrence: the return of symptoms after recovery
157 
(after 6 months) 
 
9.4 Instruments  
Clinical Global Impressiom
150 
 CGI is structured in 3 items. item 1 of the Clinical Global Impression that assesses the severity of 
the disease by dividing it into 7 points (0 = has not been assessed, 1 = normal (absence of mental 
illness), 2=only marginally ill 3 = mildly ill, 4 = moderately ill, 5 = greatly ill, 6 = severely ill, 7 = 
is among the sickest patients)  and the item 2 that assesses the improvement from baseline (0= has 
not been assessed, 1= much improved, 2= moderately improved, 3= slightly improved, 4= no 
change, 5= slightly worse, 6= moderately worse, 7= much worse). 
Item 3 assesses the effectiveness of treatment and side effects. 
According to the classification of Wooderson et al 2014
206
 we split the outcome of the TRD patients  
by the CGI scale item 2 score reported after the one year follow-up (T5): “Good outcome” were the 
subjects “much improved” or “very much improved”(score 1-2 item 2), “Intermediate outcome” 
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were the patients “slightly improved”(score 3 item 2) and “Poor outcome” were the patients “no 
change” or “worse” (score 4-5-6-7 item 2). 
Montgomery-Asberg Depression Rating Scale (MADRS)
 149 
MADRS is composed of 10 items that explore the mood, feelings of discomfort (internal stress), 
sleep, appetite, concentration ability, initiative, emotional involvement, pessimism and the desire to 
live. Each item is rated on a 7-point scale (0 = absence of symptom; 7= very serious), the total score 
is calculated by the sum of the responses to the 10 items and must be between 0 and 27 (higher 
scores indicate a greater impairment). 
Structured Clinical Interview for DSM-IV-Axis I Disorders/Patient edition (SCID-I/P)
 75 
SCID-I/P is a semistructured clinical interview developed by Spitzer and colleagues (1992) to 
diagnose Axis I disorders according to DSM-III and then updated according to DSM-IV criteria 
(Ventura et al., 1998). It is composed of 9 modules containing all the questions to investigate the 
existence of criteria for different diagnostic categories (mood disorders, anxiety disorders, 
substance abuse, eating disorders, etc.), as well as providing an assessment of gravity. Each module 
is independent and can be used separately from the other according to specific searches. The 
interview follows hierarchical rules that, if the presence of a disorder excludes another, the latter is 
not under investigation. One to two hours are required to complete the interview, depending on the 
complexity of subject's psychiatric history and his/her ability to clearly describe current symptoms 
or history. 
Longitudinal Follow up Evaluation (LIFE)
 249 
The LIFE chart was the primary measure used to assess long-term symptom severity. The LIFE 
chart is widely used follow-up scale that allows weekly or monthly symptomatic status of patients 
to be assessed retrospectively at follow up intervals of 6 months or longer. (up to 96 months). 
Symptoms are ordinarily rated on a six-point scale using the Psychiatric Rating Scales (PSR)
249
. 
Although operationally linked to the Research Diagnostic Criteria
178
 in the original design, the PSR 
has been subsequently adopted for use with the Diagnostic and Statistical Manual of Mental 
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Disorders (DSM)
177
. 
 
9.5 Statistical analyses 
 
Statistical Package for Social Science (SPSS) software (version 15 for Windows) was used to 
analyze the data: means (with standard deviations), medians (with inter-quartile ranges (IQR) and 
percentages were used as appropriate.  
Descriptive analyses were used to determine sample’s demographic and diagnostic characteristics. 
The differences in continuous variables between the two diagnostic groups were examined using the 
Student's t-test and the Wilcoxon-Mann-Whitney test for dependent variables not distributed 
according to a normal curve. The proportions in contingency tables were compared using the Chi-
square test using the Yates correction test. 
 
10. RESULTS 
Forty-seven subjects with inclusion and exclusion criteria (TRd=Treatment Resistant depressed) 
subjects have been enrolled in the study from January 2008 to December 2009.  
Mean age was 53+12 (range 21-70) and the sample was mainly composed by female 74.4% (n=35) 
while male subjects represented  the 25.5% (n=12) of population. Majority of patients had a high 
education level: high school diploma in 46.8% (n=22) and a university degree in 14.9% (n=7) while 
21.3% (n=10) had an intermediate level education and 17% (n=8) had a primary education level.  
Married patients were the majority of sample (66%; n=31). Most persons had a full-time job 
(40.4%; n=19) 23.4% were housewives (n=11),  and 21.3%; were retired (n=10) (Table 3). 
Depressive episode in Bipolar Disorder (BD) was more frequent diagnosed than in Unipolar 
Disorder (UD) (n=34; 72.3% vs n=13; 27.7%) and the melancholic subtype was most frequent one 
(n=34; 72.3%)  (Table 4). 
Twenty-eight patients (59.6%) fulfilled criteria for stage I Thase and Rush resistance. Stage II was 
represented in 8 patients (17%), stage III in 10 patients (21.3%), while  only 1 patient (2.1%) of 
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patients showed  a stage IV resistance (Table 5). 
The mean age of onset of affective disorder was 31+13 years (range 15-68 years). In all subjects  
first episode was characterized as depressive, the mean number of previous depressive episodes was 
3.55 ± 2.49 and the mean number of previous hospitalizations was 2.94 ± 2.00, current depressive 
episode had a mean duration of 8+6 months (Table 4).   
The majority of the sample (n= 31, 66%) had at least one comorbidity axis I disorder, mainly 
represented by an anxiety disorder, specifically  Panic Disorder (n=25; 53.2%). A second 
comorbidity disorder was reported in 8 patients (17%). First co-morbidity mean age of onset were 
28+15. The majority of the sample (n=28 59.6%) had somatic comorbidity too, especially 
Cardiovascular disease (CD) (n=17; 36.2%) (Table 4). 
A history of suicide attempts was reported in 14 patients (29,8%), family history for suicide was 
reported by 4 patients (8.5%) and one patient died for suicide during follow-up (Table 4). 
Regarding the classification of treatment resistance, 29 patients (61.7%) were found to be resistant 
to mono-therapy , while 18 subjects (38,3%) revealed a resistance  to combination-therapy. Among 
these last, one third (n=6) presented resistance to TCA plus SSRI (table 6), while among patients 
resistant to  monotherapy, 13 (44.8%) did not respond to a TCA, 9 (31%) to a SSRI, 6 (20.7%) to a 
SNRI antidepressant (Table 5). 
A high percent of patients (n=19; 40.4%) was found to be resistant during the course of current 
depressive episode, after augmentation therapy with Carbolithium, Lamotrigine and Pramipexole 
before hospitalization (Table 5). 
More than a quarter of the sample (n=13; 27.7%) had been treated with an ECT cycle during 
previous episodes (Table 5). 
Data of all 47 patients during the prospective follow-up year show that11 patients (23.4%) did not 
have a response to drug therapy in the follow up year and may therefore be considered as patients 
with chronic depression. Six patients, although presenting a therapeutic response during the 12 
months follow-up, did not have a remission (MADRS never≤12). The remaining 30 (63.8%) 
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patients had a remission. Seventeen (36.2%) patients had total remission (MADRS≤12 at least 8 
weeks)  and 13 (27.6%) had a partial remission (improvement of symptoms that do not meet DSM-
IV criteria for the depressive episode but there are residual symptoms or MADRS≤12 less than two 
months). Of these 30 remitted patients, nine (19.1%) had a recovery, five (10.7%) had a relapse and 
1 patient (2.1%) had a recurrence, and of these six patients later, only one patient (p with relapse) 
has a total remission (Table 6). 
During the year of follow-up 11 patients (23.4%) was treated with ECT: two of them had response 
but not remission, 8  had response followed by remission and one did not respond  (table 5). 
During the follow-up also, one patient died instead for suicide (between 8 e 16 week, after the TEC) 
and 6 patients (12.8%) switched manic or mixed episode: all of them had a diagnosis of Bipolar I 
Disorder and were taking mood stabilizers (table 6). 
According to Item 1 of the CGI, at T0  13 patients (27.7%) was seriously ill (score=6),  21 (44.7 %) 
greatly ill (score 5) and 13 (27.7%) was moderately  ill (score=4). At the end of follow up (T5), 2 
patients (4.3%) were seriously ill, 9 (19.1%)  were greatly ill, 12 (25.5%) were moderately ill , 15 
(32%) were mildly ill, 7 (14.9%) were only marginally ill, 1 was normal (absence of mental illness), 
1  not be evaluated because died (deceased).  According to the classification of Wooderson et al 
2014 a good outcome were found in 21 patients (44.6%)  who were “much improved” or “very 
much improved”) at item 2 of CGI, an intermediate outcome in 15 (31.9%) patients who were 
“slightly improved” and a poor outcome 11 (23.4%) patients with a score corresponding “no 
change” or “worse”). 
We then compared the variables described above between two subgroups according to diagnosis (34 
Bipolar ans 13 Unipolar). The only difference was the duration of the current episode, which was 
longer in Unipolar as compared to Bipolar patients (13.15 ± 8.35 vs 6.09 ± 4.54 p = 0.000). 
 A second step of our study regarded the comparison between patients with TRD and a sample of 47 
depressed patients (Rd) matched by sex and diagnosis, who were responsive to antidepressive 
treatment and who went through to the same evaluations. 
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Mean age of Rd at baseline was 48+16 (range 20-70) most patients were female 85.1% (n=40) 
while male represented the 14.9% (n=7) of population. Majority of patients had a high education 
level (high school diploma in 29, 61.7% and university degree in 8 12.8%) while 14.9% (n=7) had a 
intermediate level education and 10.6% (n=5) had a primary level education.  Married patients were 
63,8%; (n=30), while single were 23.4 %. There was a high frequency of regularly employed 
peoples (59,6%; n=28) and the rest of the sample did not work and were housewives in 19.1% ( n= 
9) or retired in 12.8% (n=6). 
Unipolar depression was more  frequent diagnosed than bipolar depression (n=30; 63.8%; vs n=17;  
36,2%) and the most frequent subtype (n=30, 63.8%) was atypical one (table7). The mean age at 
onset of affective disorder was 29+10 years (range 14-57 years). Polarity of onset was depressive in 
all patients and the mean number of previous depressive episodes was 2.38 ± 1.94. The mean 
number of previous hospitalizations was 2±0.6 (Table 8). 
The current depressive episode had a mean duration of 4+3 months. Comorbidity was not frequent 
and was detected only in 34% of patients (n=16) who suffered from anxiety disorders, specifically   
Panic Disorder (n=14; 29.8%;) mean age at onset of comorbid disorder were 27+10. The majority 
of the sample (n=32; 68%;) didn’t have somatic comorbidity too. Only one patient attempted 
suicide (2.1%) and two had a family history of suicide (4.3% ) (Table7). 
One patient didn’t have remission, 39 patients (83%) had total remission and 7 (14.9%) had partial 
remission. Of these  46 patients, 28 patients (59.5%) had a recovery, eight (17%) had a relapse and 
three patients (6.4%) had a recurrence. Of  the patients with relapses and recurrence, five (10.6%) 
achieved a subsequent total remission and six a partial remission (12.8%) (Table 6). During the year 
of follow-up no one patients was treated with ECT or committed suicide attempts, and only one 
patient presented a manic/mixed switch.  
According to item 1 of the Clinical Global Impression, it is noted that at T0 30 patients (63.8%) 
were moderately ill (score=4) and 16 (34 %) greatly ill (score=5), at the end of follow-up  period 
(T5) 24 (51.1%) were normal, 19 (40.4%)  marginally sick and 4 (8.5%) mildly ill (table 6). 
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Finally we compared demographic and clinical variables in the two samples (TRd vs Rd) (table 7, 
table 8). 
There were no statistically significant differences between the two samples in gender, mean age, 
marital status, education and employment. 
Compared to Rd, TRd had significantly more depressive episodes (3.55 ± 2:49 vs 2.38±1.94 p= 
0,005), suicide attempts (SA) (0.43 ± 0.80 vs 0.02 ± 0:15 p = 0.000), higher number of previous 
hospitalizations (2.94±0.23 vs 2±0.6, p=0.000) and lenght of current episode (8.04±6.57 vs 
4.51±3.30 p=0.003). They more frequently had a diagnosis of bipolar than unipolar depression 
(34/47 vs 17/47, p = 0.000) and melancholic subtype was significantly more represented in the TRd 
(34/47 vs 17/47 p= 0.000) 
Axis I comorbidity was significantly more represented in the TRd (31/47 vs 16/47, p=0.002;) and 
specifically Panic Diosrder was significantly more frequent in TRd vs Rd (25/47 vs 14/47 p=0.032). 
Somatic comorbidity was detected more frequently in TRd (28/47 vs 15/47, p=0.007). TRd were 
more treated with ECT than the other group both in the past history (13/47 vs 1/47, p = 0.013) and 
during the current episode (11/47 vs 0/47 p = 0.001).  
Mean scores at item 1 of CGI both at T0 and T5 were significantly higher in TRd as compared to 
Rd (T0: 5 ± 0.75 vs 4.38 ± 0.53 p = 0.000; T5: 3.51 ± 1.27 vs 1.57± 0.65  p = 0.000). As regards the 
variables “response” and “remission”, they were significantly more frequent in Rd vs TRd (36/47 vs 
47/47, p = 0.001; 1:57 ± 0.9 vs 1.3 ± 1.27, p = 0.000) . 
 
11. DISCUSSION 
In this study we firstly described demographic and clinical characteristics of depressed patients with 
a history of resistance to antidepressant treatment (TRd), secondly, we compared such 
characteristics between TRd and a sample of depressed patients without a history of resistance to 
antidepressants treatment (Rd- Responder depressives). 
Finally,  we compared the course and outcome features of TRd and Rd patients who were 
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prospectively followed up for 1 year. 
About 75% of our TRD population was composed by middle aged females. This result seems to 
confirm the literature data that indicate an association between female gender and treatment 
resistance. However, recent surveys do not report any difference in response to treatment depending 
on age and gender: the controversies on this issue may be attributed to the lack of homogeneity of 
inclusion criteria: samples of depressed patients, including those with TRD, female gender is largely 
preponderant because of the gender difference in prevalence rates of depression
71
. However,  female 
gender has not generally found to be a predictor of worse outcome
72 
even though recent evidence 
indicate that women patients may be less responsive than men to tricyclics and may preferentially 
respond to SSRIs or MAOIs
9
. 
As regards age at onset, the literature is too sparse to draw any real conclusions. Akiskal et al 
160 
reported that early onset of depression with a positive family history for affective disorders is 
associated with a chronic course of illness, which tends to result in lower antidepressant response 
rates and incomplete remission of depressive symptoms. In a study of Klein and collegues
161
 on 
chronic depression, instead, early onset was not found to be a predictor of non-response. 
Nevertheless, late onset depression is associated with several important features that may lead to 
treatment resistance. For example late onset depression is often accompanied by psychotic 
symptoms, which would be less responsive to antidepressant medication, and by several medical 
conditions that may affect both a timely diagnosis and the treatment of depression
162,163
. Actually, 
there is a high risk of pseudo-resistance in geriatric patients, if the diagnosis of an organic mood 
disorder is missed or if the patient is unable to reach an adequate dosage of medication due to 
greater sensitivity to side effects
9,164
.  
 
Specifically, clinician should pay careful attention to a possible incipit dementia in depressed 
geriatric patients. 
Our sample of TRd  frequently (59.6%) had somatic comorbidity which was more represented than 
in Rd. 
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In particular patients showed a high frequency of cardiovascular diseases confirming the close 
association between heart disease and major depression reported in literature
199
. The prevalence of 
depression disorder is estimated at between 15%–20% in coronary heart disease (CHD) population, 
while clinically relevant depressive symptoms have been found in up to 40% of patients with 
CHD
200
. Moreover, the presence of depression symptoms or syndrome is widely documented to 
lead to adverse CHD prognosis, particularly with high morbidity, mortality and poor quality of 
life
199
.  For this reason it has been hypothesized that depression treatment in the CHD population 
could ameliorate an otherwise poor prognosis.  These results strongly suggest a careful cardiac 
screening whenever a clinician is managing a TRd. Recently, a collaborative care, a multi-
professional approach, has emerged as a potentially promising model for health care among 
populations with psychiatric disorder comorbid with chronic diseases such as diabetes and CHD
201
.  
Our sample with TRD was mostly bipolar (I and II). These findings appear to agree with recent 
reports showing an association of bipolarity features with treatment resistance
28
. For example the 
Polish DEP-BI study of Rybakowski et al
165
, conducted on 880 patients throughout 16 psychiatric 
facilities in Poland, with the aim to evaluate the prevalence of Bipolar Disorder among depressive 
patients, showed that percentage of patients with TRD was significantly higher among bipolar 
patients compared to unipolar patients. In the same study, authors compared the subtypes of 
depression and found that the highest percentage of treatment resistance (defined as a lack of 
response to 3 or more antidepressant treatment trials) occurred in patients with bipolar spectrum 
disorder, defined as a clinical condition between bipolar II and unipolar depression
152,197 
. This may 
suggest that one of the reasons for resistance may be an unrecognized bipolarity
166
. 
According to some authors, a bipolar treatment resistant depression should be regarded as a 
“pseudo-resistance” 
In this line, some authors have suggested that treatment resistance in unipolar depression could be 
an iatrogenic effect consequential to an incorrect prescription of antidepressants in absence of mood 
stabilizers to a patient with a unrecognized bipolar diathesis
65,80
. There is support for this hypothesis 
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in some results of antidepressant therapy frequently reported in resistant unipolar depression, for 
example the phenomenon of "wear-off": an initial response but inability to maintain improvement 
or “treatment refractoriness”81: progressive diminution of response to successive trials of 
antidepressants. Another feature of a bipolar diathesis is the presence of symptoms such irritability, 
or psychomotor restlessness, or ideas acceleration during a depressive episode, in connection or not 
with the intake of antidepressants, that suggest an “attenuated mixed state” or “mixed depressive 
syndrome”80,81. Consequently, constant attention to potential indicators of bipolarity may help the 
clinician to recognize hidden cases of bipolar disorder among their TRd and then to adopt a more 
appropriate treatment management.  A number of researches have attempted to identify clinic 
features associated with bipolarity, including a family history of bipolar disorder , disease onset at 
early age, melancholic subtype, comorbidity with anxiety disorder, suicide risk and higher 
frequency of depressive episode
153,185,186
. Several of these clinic features are present in our TRd 
sample.  For example, almost half of our TRD patients had a history of suicide attempts; family 
history of suicide was present in the 8.5% (n=4) of the sample and one patient died for suicide 
during follow-up (between the evaluations T2-T3). These data confirm high risk of suicide in TRD 
population
28
. Suicidal ideation was previously reported as a predictor of non-response in single 
antidepressant trials. STAR*D
202
 (Sequenced Treatment Alternatives to Relieve Depression)  
supported that depression with a history of suicidal behavior may be a marker for a substantially 
more severe and debilitating form of depression for which more aggressive clinical management is 
required.  Recently, Souery et all
28
 in a study of a sample of 702 patients with DSM-IV major 
depressive disorder, found suicidal risk in depressive episode a clinical factor associated with  non-
response to antidepressant therapy. 
In our sample of TRd the melancholic was more frequent than atypical and psychotic subtypes. Our 
finding confirm a recent European multicenter study
28
: the presence of melancholic features during 
the episode is a clinical variable indicating treatment resistance.  
The co-occurrence of depressed mood and agitation in both melancholia and bipolar mixed states 
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was described in some reports, suggesting that the two disorders could share a common 
pathophysiology. The sensitivity to the stimulatory effects of antidepressants with an increase in 
suicidal risk in patients with both melancholia and mixed states could corroborate this 
observation
179
. These findings and overall considerations do suggest that melancholia as currently 
defined is more closely aligned with the depressive and/or mixed phase of bipolar disorder. Given 
the high suicidality displayed by many of these patients, the practice of treating them with 
antidepressant monotherapy needs re-evaluation
154
.   
Moreover, several authors
180,181,182
 point out  that melancholic depression is characterized by an 
earlier age at onset, longer duration of illness, higher frequency of episodes, more lifetime suicide 
attempts and a positive family history of psychiatric disorder. These features therefore, may 
represent a marker for bipolarity in patients with melancholic subtype of MDD
183  
accounting for 
the poor response oh these patients.
  
A single or multiple axis I comorbidity was found in the majority of our sample. Psychiatric 
comorbidity has been associated with poor response to treatments in several studies on depression 
and our findings seem to support these results. In particular, two thirds of our TRD patients received 
a diagnosis of a comorbid anxiety disorder, especially Panic Disorder. STAR*D reported
203,204
 that 
comorbid anxiety disorders is always associated with poor outcomes, suggesting the importance of 
a careful evaluation of anxiety symptoms during the acute management of patients with Major 
Depression. Recently Souery et al.
28
 reported that comorbid anxiety disorder is the most powerful 
factor associated with TRD. Depressed patients with anxiety features tend to be more severely 
depressed than patients with depression alone. In particular comorbidity with panic features or a 
lifetime history of panic-disorder has been linked not only a greater depression severity
189,190,191
 but 
also to a poorer psychosocial functioning
191
, a greater risk for suicide
167
, and poorer response to 
both psychotherapeutic
188,192
 and pharmacologic treatments
187,188,189  
with an incomplete remission 
of symptoms and a significantly slower rate of recovery of a major depressive episode
9,187,168
.  
Several studies linked the comorbidity of Depression and Panic Disorder with a diagnosis of 
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Bipolar Spectrum Disorder: Ben Abla 2006 et al
196
 have reported that, compared with Unipolar 
Disorder, Bipolar Disorder displays a higher frequency of somatic comorbidity and a larger amount 
of anxiety manifestations; Kiejna et al in a national multisite study observed that patients with 
Bipolar compared to those with Unipolar Mood Disorder had significantly more frequently panick 
attacks
197
 and finally, a recent systematic review of prospective studies (Faedda et al 2014), shows 
that among the clinical risk factors of Bipolar Disorder were anxiety disorders especially Panic 
Disorder
198 
Often, these comorbid disorders are missed or are sub-optimally treated, and they can confound 
both the evaluation and treatment of Mood Disorder. It is therefore important to systematically 
evaluate patients with TRD for the presence of  other comorbid Axis I disorders, in particular with a 
complete screening for anxiety symptoms and disorders. 
All our TRd had a depressive polarity of onset of affective disorder. This result could represent a 
new line of research in TRD. First episode of illness is often depressive in adolescence or young 
adulthood in Bipolar Disorder
205
 . 
In our sample with TRD we also found a longer length of the current episode, a higher number of 
previous depressive episodes and of previous hospitalizations compared with the Rd sample. This 
finding  supports data from the literature
9,28 
that report these variables to be associated  with poor 
response to antidepressants treatment. Interestingly, the same features (in particular the high 
frequency of recurrences depression), has been described as clinical indicators of bipolarity.   
It has been reported that nonresponse to the first antidepressant trial increased by 1,6-fold the risk of 
treatment resistance during the last episode
28
. 
We carefully evaluated the  previous treatment of TRD patients included in the study sample and we 
found a personal history of treatment resistance in almost the totality of sample. Data from the 
STAR*D on the gradual reduction of the probability of response to antidepressant treatment after 
the second trial, would seem to support the validity of this concept 
4,14,15
; A patient with a personal 
history of lack of response to therapy will have a lower probability of response and remission in 
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future treatments. In European multicenter study Sourey et all
28
 found nonresponse to a first 
antidepressant lifetime and history of recurrent depression to be associated with TRD during the last 
episode. These aspects may be important as previously poorly detected. 
38,3% of our TRD sample was resistant to an antidepressant combination therapy, in almost all 
cases represented by TCA plus SSRI. Among the patients who show resistance to a monotherapy 
who were about two thirds, the majority was in treatment with TCA or SSRI. 
Nineteen of our TRd were found to be resistant during the course of current depressive episode, 
after augmentation therapy with Lithium Salts, Lamotrigine and Pramipexole before hospitalization. 
Moreover more than a quarter of the sample had been treated with an ECT course during previous 
episodes: these findings may indicate a particular severe condition of resistance of majority of our 
patients. 
With regard to ECT, during the year of follow-up nine of the eleven patients who have ECT showed 
a remission. This shows that ECT is an effective therapy in treatment-resistant depression. 
At present ECT is no longer a first-line treatment for severe depression, but medication resistance 
has become its primary indication, and patients referred to ECT are frequently chronic and more 
severely ill
193,194. 
In a naturalistic long-term follow-up ranging from 6 to 30 months of 37 bipolar I and II patients 
with severe depression or mixed state resistant to pharmacological treatment who responded to 
ECT, Medda et al
195
 reported a relapse rate of 36%. The positive impact of ECT on clinical course 
of such severe treatment-resistant patients with bipolar disorders is suggested by the high mean 
number of follow up weeks spent in remission after treatment with ECT (38.9±34.5 weeks). 
During the follow up year the majority of the TRD patients examined (63.8%) have a remission and 
about 20% of the sample have a recovery.
 
There are no directly comparable studies with which we 
can compare our findings.  To the best of our knowledge, data on this field are scarce, and only one 
of the few studies that provide a follow-up
170
, treatment-resistant depressive patients discharged 
from a tertiary care, followed for 8 to 84 months, reported a full remission in 60.2% of the sample  
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(n=150). About half of these last  (48.3%) showed sustained recovery. The outcome in our study is 
somewhat worse, in terms of proportion of patients meeting recovery criteria after follow-up 
(19.1% vs 48.3%). One explanation could be the shorter duration of follow-up in our study, since it 
has been observed that the longer is the follow-up the higher is the chance of recovery
170 
 
12. LIMITATIONS 
Some limitations of the study should be highlighted :  
Retrospective assessment represents one of the limitations for the risk of recollection biases 
especially as regards the data on drug treatment. A factor which could reduce this bias is that all the 
sample of TRd was hospitalized, and underwent extensive clinical evaluations by direct interview 
which involved interviews to family members or friends as well as the examination of previous 
medical records. 
Another limitation is the paucity of the sample size, which prevent us to perform more detailed 
analyses, makes the results liable to imprecisions, and hinder us to draw firm conclusions. 
Since most of the sample presented a low stage of resistance (stage I Thase and Rush resistance), it 
was more likely for these patients to have a good outcome. On the other hand, however, the TRd 
sample consisted of patients with high levels of cross-sectional symptom severity, as evidenced by 
the high MADRS scores, the long duration of current episode, the high rates of suicide. Moreover, 
as regards treatments, most of TRd underwent ECT previously and received augmentation therapy 
during the current episode, suggesting a particular severe condition of resistance. 
In this study, we did not included latest staging method for treatment resistance and treatment 
adequacy was defined as having received at least 4 weeks of the antidepressant at the adequate 
dose. This duration could not be considered sufficient to ascertain a lack of response, however, this 
time frame is consistent with usual clinical practice. 
Another source of bias may result from having included both unipolar and bipolar patients 
increasing the heterogeneity of TRD sample. This is frequently cited as limitation in TRD 
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research
171, 172. 
We also acknowledge that there have been recent attempts to define treatment-
resistant bipolar depression
173
 reflecting the somewhat different treatment approaches usually 
undertaken, though some have suggested that the concept applied to unipolar MDD can also be 
applied to bipolar depression
174
. The comparison between unipolar or bipolar TRD, indeed, did not 
show significant clinical differences. Since our aim was to explore TRD in a “real world sample”, 
the inclusion of bipolar subtype allows us to have a more representative sample of clinical reality. 
It’s also true that the inclusion of a bipolar resistant depression group could be seen to reduce direct 
comparability with previous long-term follow-up studies of MDD. In our study, however, the 
comparison between the prospective course of 1 year in TRD and Rd patients is effective because 
the bipolar depressed patients are also included in the group of patients Rd.  
In our study, TRd are hospitalized, while 47 depressed-responder patients are recruited in 
outpatients service of our clinic and then consequently, Rd are less seriously ill, but solely  
including patients with positive response to antidepressant therapy initiated not later than two 
months before the inclusion in the study, allows to exclude patients already stabilized for several 
months and then at lower risk of relapse. Another limitation is that the follow up duration in this 
study was relatively short compared to previous follow up study of unipolar major depression
175,176 
though is substantially longer than other published studies in this area. 
Finally, the cohort in this study was not a random population based sample but was followed-up 
from a specialist service for patients with treatment resistant affective disorders. Consequently, this 
cohort likely represents the more severe end of the depressive spectrum, which may limit the 
generalisability of the findings to other treatment-resistant samples outside tertiary care. 
 
13. CONCLUSION 
 
In a potentially chronic and relapsing condition such as treatment-resistant depression, studies 
looking at longitudinal outcome are particularly relevant. In this study we have been evaluated an 
TRD inpatients sample, our findings seem characterize TRD population as mainly composed by 
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middle aged female, married, with high level of education.  TRD patients report a  personal  history 
of treatment resistance and personal and familiar history of suicide attempts. A bipolar diathesis 
may represent an important clinical characteristics of TRD patients, too. Treatment resistance 
appears mainly related to melancholic episodes, duration of the current episode, number of previous 
depressive episodes and hospitalizations, and suicide risk. Somatic comorbidity (specifically 
cardiovascular diseases), Axis I disorder comorbidity, particularly anxiety disorders (Panic 
Disorder) may be highly frequent in TRD population, as already evidenced in Souery’s European 
Multicenter Study.    
Although TRD is a common clinical occurrence, a greater consensus is required regarding the 
definition and the operational criteria for staging response and resistance to antidepressant 
treatments.  
Predictive factors must be identified to recognize patients who are more likely to respond to 
antidepressant trials. 
Pharmacogenomic studies are also needed to assist in identifying biological predictive factors.    
Future research, besides the identification of demographic and clinical factors associated with TRD,  
should also investigate genetic polymorphism and new molecular technologies such as gene 
expression and proteomics, which may further contribute to clinical and genetic characterization of 
the subphenotypes of TRD. 
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14. TABLES AND GRAPHS 
Table 1 Staging methods (Changed from Ruhé et al., 2012)
21 
 
 
A. Antidepressant Treatment History Form (Sackeim et al., 1990)
22 
 
 
0 No treatment or no drugs with known psychotropic actions 
1. Any drug <4 weeks or less than minimum adequate daily dose. For ECT 1–3 ECT sessions 
For psychotic MDD plus chlorpromazine equivalent 400 or b3 weeks 
2. Any drug ≥4 weeks at less than minimum adequate daily dose .For ECT 4–6 ECT sessions. 
For psychotic MDD always when chlorpromazine equivalent 400 or 3 weeks or when 
monotherapy with antipsychotic (chlorpromazine equivalent ≥400 and ≥3 weeks 
3. Any drug ≥4 weeks at minimum adequate daily dose .For ECT 7–9 unilateral ECT sessions. 
For psychotic MDD plus chlorpromazine equivalent ≥400 and ≥3 weeks 
4. Any drug ≥4 weeks at higher than minimum adequate daily dose,  or any drug at level 3 
augmented with lithium ≥2 weeks. For ECT 10–12 unilateral/7–9 bilateral ECT sessions. 
For psychotic MDD plus chlorpromazine equivalent ≥400 and ≥3 weeks 
5. Any drug at level 4 augmented with lithium ≥2 weeks. For ECT ≥13 unilateral/≥10 bilateral 
ECT sessions. For psychotic MDD plus chlorpromazine equivalent ≥400 and ≥3 weeks 
 
 
 
B. Thase and Rush Method (Thase&Rush, 1997)
25 
 
  Stage 0:  Any medication trials, to date, judged to be inadequate 
  Stage I:  Failure of at least 1 adequate trial of 1 major class of antidepressants 
  Stage II:  Failure of at least 2 adequate trials of at least 2 distinctly different  
                                               classes of antidepressants             
  Stage III:        Stage II resistance plus failure of an adequate trial of TCA 
  Stage IV:        Stage III plus failure of an adequate trial of an MAOI 
  Stage V:         Stage IV resistance plus a course of bilateral electroconvulsive therapy 
 
 
C. The European Staging Method (Souery et al., 1999)
36 
 
Staging Definition Duration of trial 
A. Non-
responder 
Non-responder to 1 adequate trial of TCA, SSRI, IMAO, 
SNRI, ECT other antidepressant(s) 
6-8 weeks 
B. TRD Resistance to 1 or more adequate antidepressant trials TRD1: 12-16 weeks 
TRD2: 18-24 weeks 
TRD3: 24-32 weeks 
TRD4: 30-40 weeks 
TRD5: 36 weeks - 1 
year 
C.Chronic  
resistant 
depression 
(CRD
) 
Resistance to several antidepressant trials, including 
augmentation strategy 
At least 12 months 
1 
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D. Massachusetts General Hospital Staging Method (Fava, 2003)
8 
 
Definition Score 
1. No response to each adequate (at least 6 weeks of an adequate dosage 
of an antidepressant) trial of marketed antidepressant generates an overall 
score of resistance. 
1 point for trial 
2. Optimization of dose, optimization of duration, and augmentation or 
combination of each trial (based on the Massachusetts general Hospital or 
Antidepressant treatment Response Questionnaire) increase the overall 
score 
0.5 point per 
optimization or 
strategy 
3. Electroconvulsive therapy 3 point 
 
 
 
 
 
 
 
E. Maudsley Staging Model (Fekadu et al., 2009)
6 
 
Parameter/Dimension Parameter specification Score 
Duration Acute (≤ 12 months) 
Subacute (13-24 months) 
Chronic (> 24 months) 
1 
2 
3 
Symptom severity (at baseline) Subsyndromal 
Syndromal 
       Mild 
       Moderate 
       Severe without psychosis 
       Severe with psychosis 
1 
 
2 
3 
4 
5 
Treatment failures antidepressant Level 1: 1-2 drugs 
Level 2: 3-4 drugs 
Level 3: 5-6 drugs 
Level 4: 7-10 drugs 
Level 5: > 10 drugs 
1 
2 
3 
4 
5 
Augmentation Not used 
Used 
0 
1 
Electroconvulsive therapy Not used 
Used 
0 
1 
Total  3-15 
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Table 2 Differential diagnoses (causes of pseudo-resistance to treatment) ( Lattanzi et al., 
2008
225
) 
 
 
Low doses of the antidepressant 
 
Inadequate duration of trial 
 
Metabolic factors 
            “Rapid metabolizer” genotype 
            Concomitant use of drugs that accelerate the metabolism of antidepressant 
 
Inadequate compliance  
 
Somatic comorbidity 
            Endocrine disease (thyroid disease) 
            Neurological disease 
            Taking madications that can cause expressive symptoms (glucocorticoids, 
            antihypertensive,  immunosuppressants) 
 
Psychiatric comorbidity 
             Anxiety Disorder (Panic Disorder) 
             Substance abuse 
             Personality disorder? 
     
Misdiagnosis (depression subtype) 
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Table 3: Demographic features in a sample of 47 patients with Treatment Resistant 
Depression (TRd) 
 Mean SD 
Age 53 12 
  N % 
Gender    
Male  12 25.5 
Female 35 74.5 
Marital status    
Married/Unmarried cohabiting  31 66.0 
Single 11 23.4 
Post-marital/Widowed/Divorced 5 10.7 
Education    
 High 29 61.7 
 Low 18 38.3 
Employment status    
Employed 19 40.4 
Unemployed 7      14.9 
Housewife/Retired/Student 21 44.7 
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Table 4: Clinical features in a sample of 47 patients with Treatment Resistant Depression 
(TRd) 
 Mean SD 
Age of onset 31 13.0 
Duration of current episode (months) 8 6.0 
Previous depressives episodes 3.55 2.49 
Previous hospitalizations 2.9 2.0 
 N % 
Principal Diagnoses    
Bipolar Depression 34 72.3 
Unipolar Depression 13 27.7 
Depressive Subtype   
Melancholic 34 72.3 
Atypic 10 21.3 
Psychotic 3 6.4 
   
Lifetime Suicide Attempts 14 29.8 
Suicide Attempts during follow-up 1 2.1 
   
   
Somatic comorbidity 28 59,6 
Cardiovascular diseases 17 36.2 
Thyroid diseases 6 12.0 
Diabetes 3 6,4 
Other diseases 13 27.7 
Psychiatric comorbidity 31 66.0 
Panic Disorder 25 53.2 
Previous ECT 13 27.7 
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Table 5: Stadiation of treatment resistance in a sample of 47 patients with Treatment Resistant 
Depression (TRd) 
 N % 
Stage of Resistance (Thase & Rush criteria)   
Stage I 28 59.6 
Stage II 8 17.0 
Stage III 10 21.3 
Stage IV 1 2.1 
Monotherapy 29  61,7 
SSRI   9  31.0 
TCA 13  44.8 
SNRI  6  20.7 
BUPROPION 1  3.4 
CombinationTherapy 18  38.3 
SSRI+TCA  9 50.0 
SSRI+SNRI  2  11.1    
SSRI+NaSSa  2  11.1 
TCA+SNRI  2  11.1 
SNRI+NaSSa  2  11.1 
IMAO+SARI  1    5.6 
Resistance to Previous augmentation trials 19  40.4 
 Carbolithium  2 10.5 
 Lamotrigine 5  26.3 
Pramipexole 6 31.5 
Lithium+lamotrigine 1 5.2 
Lithium+Pramipexole 4  21.0 
Lamotrigine+Tryptophn 1  3.5 
ECT current episode 11  23.4 
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Table 6: Outcome. Comparison between TRd and Rd 
 
     TRd 
    N=47 
 
 
       Rd 
       N=47 
 STATISTICS 
 
   N    %  N    % p value* 
Response  to treatment      36    76.6 47   100   0.001** 
No response       11    23.4 -   
No remission      17    36.2  1      2.1  
Remission       30    63.8 46   97.8    0.001** 
Total Remission      17    36.2 39   83.0  
Partial Remission      13    27.6  7   14.9  
Recovery       9        19.1 28    59.5  
Relapse/Ricurrence        6        12.8 11   23.4 0.765 
Switch       6        12.8   1    2.1     0.413** 
   Mean   SD      Mean   SD     p value*** 
CGI T0    5.00    1.15  4.4   0.5 0.000 
CGI T5 3.51        1.30  1.6   0.6 0.000 
*Chi square test 
**Chi square test Yates correction 
***Wilcoxon rank sum test 
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Table 7: Clinical features. Comparison between TRd and Rd  
 
                 
                 TRd 
              
                 
                 Rd     
           
STATISTICS STATISTICS 
  N 
          
         % 
 
        N 
        
         % 
 
P value 
(Chi square 
test) 
P value 
 (Chi square test Yates 
correction) 
 
PRIMARY 
DIAGNOSIS  
 
34* 
 
72.3 
 
17* 
 
36.2  0.000 
SUBTYPE 34** 72.3 17** 36.2  
 
0.000 
 
 
PSYCHIATRIST 
COMORBDITY 
31 66 16 34  0.002 
 
PANIC 
DISORDER 
 
25 
 
53.2 
 
14 
 
29.8 
 
0.032 
 
0.032 
 
SOMATIC 
COMORBIDITY 
28 59.6 15 32 0.000  
 
SUICIDE 
ATTEMPTS 
14 29.8 1 2.1  0.007 
 
PREVIOUS 
ECT 
13 27.7 - -  
 
0.013 
 
RESPONSE 
 
36 
 
76.6 
 
47 
 
100 
 
 
 
0.001 
REMISSION 30 63.8 46 97.8  
 
              0.001 
 
ECT 11 23.4 - -  0.001 
 
*Bipolar Disorder 
** Melancholic subtype 
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Table 8:  Course characteristics. Comparison between TRd and Rd   
 
 
 TRd                Rd  STATISTICS 
  Mean±SD Mean±SD p value 
 
NUMBER OF 
PREVIOS 
DEPRESSIVE 
EPISODES 
 
3.55±2.49 2.38±1.94 0.005 
SUICIDE 
ATTEMPTS 
0.43±0.80     0.02±0.15   0.000 
 
HOSPITALIZATIONS 
 
2.94±2.00 
 
0.23±0.60 
 
0.000 
 
MEAN DURATION 
CURRENT 
EPISODE (months) 
 
 
        8.04±6.57 
 
 
4.51±3.30 
 
0.003 
 
CGI T0 
 
5.00±0.75        
 
4.38±0.53    
   
           0.000 
 
CGI T5 
 
3.51±1.27 
 
1.57±0.65   
 
0.000 
 
*Wilcoxon rank sum test 
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Figure 1. Clinical Global Impression. Comparisons between TRd and Rd at baseline and after 
one year of follow up 
 
 
 
 
 
Figure 2. Remission and response. Comparisons between TRd and Rd 
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Figure 4: Monotherapy and combination therapy in TRd 
 
 
 
Figure 5: Antidepressant monotherapy in TRd 
 
 
 50 
 
 
Figure 6: Combination therapy in TRd 
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